Equities Analysts Offer Predictions for STERIS Q2 Earnings

STERIS plc (NYSE:STE - Free Report) - Zacks Research raised their Q2 2027 earnings per share (EPS) estimates for STERIS in a research report issued to clients and investors on Wednesday, November 27th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings per share of $2.58 for the quarter, up from their previous estimate of $2.51. The consensus estimate for STERIS's current full-year earnings is $9.15 per share.

STERIS (NYSE:STE - Get Free Report) last issued its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.02. The company had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.33 billion. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The business's revenue was up 7.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.03 EPS.

A number of other research analysts also recently weighed in on the stock. Needham & Company LLC restated a "hold" rating on shares of STERIS in a report on Friday, November 8th. KeyCorp raised their target price on STERIS from $255.00 to $265.00 and gave the company an "overweight" rating in a report on Tuesday, September 3rd. Piper Sandler raised STERIS from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $230.00 to $260.00 in a report on Thursday, October 24th. StockNews.com downgraded STERIS from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, October 29th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $265.00 target price on shares of STERIS in a research report on Monday, November 18th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, STERIS presently has an average rating of "Moderate Buy" and a consensus price target of $253.00.

STERIS Stock Down 0.1 %

NYSE STE traded down $0.19 during trading on Monday, reaching $218.87. The company's stock had a trading volume of 614,590 shares, compared to its average volume of 497,856. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $21.60 billion, a PE ratio of 49.97 and a beta of 0.85. STERIS has a 1-year low of $195.50 and a 1-year high of $248.24. The business has a 50-day moving average price of $224.60 and a 200-day moving average price of $228.15.

Institutional Trading of STERIS

Several institutional investors have recently modified their holdings of the company. Massachusetts Financial Services Co. MA lifted its position in STERIS by 13.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider's stock worth $1,414,453,000 after purchasing an additional 778,613 shares during the period. Franklin Resources Inc. lifted its holdings in shares of STERIS by 171.2% during the 3rd quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider's stock worth $191,370,000 after acquiring an additional 529,308 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of STERIS by 7,418.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 309,771 shares of the medical equipment provider's stock valued at $75,132,000 after acquiring an additional 305,651 shares in the last quarter. Impax Asset Management Group plc boosted its position in shares of STERIS by 29.7% during the 2nd quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider's stock valued at $251,663,000 after acquiring an additional 263,383 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in STERIS by 1,946.3% in the second quarter. American Century Companies Inc. now owns 270,311 shares of the medical equipment provider's stock valued at $59,344,000 after acquiring an additional 257,101 shares during the period. Institutional investors and hedge funds own 94.69% of the company's stock.

Insiders Place Their Bets

In other news, CFO Michael J. Tokich sold 23,332 shares of the business's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the transaction, the chief financial officer now owns 42,930 shares in the company, valued at approximately $10,603,710. The trade was a 35.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Cary L. Majors sold 1,682 shares of the company's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the transaction, the senior vice president now directly owns 11,372 shares of the company's stock, valued at $2,471,363.04. This represents a 12.88 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.14% of the company's stock.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be given a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 1.04%. The ex-dividend date is Tuesday, November 19th. STERIS's dividend payout ratio is currently 52.05%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.